Compare Davita Inc (DVA) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Altria Group Inc — how do they compare? Davita Inc trades at $179.05 (market cap $11.29B), while Altria Group Inc trades at $71.54 (market cap $119.25B). The key difference: Altria Group Inc is far larger — about 10.6× Davita Inc's market cap, and Altria Group Inc pays a 6.22% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Altria Group Inc for 154 Days on average.
| DVA | MO | |
|---|---|---|
Market Cap | $11.29B | $119.25B |
Volume | 582,204 | 11,178,169 |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $74.92 |
52-Week Low | $103.87 | $54.72 |
Typical Hold Time | 114 Days | 154 Days |
Enterprise Value | $24.01B | $141.46B |
Dividend Yield | — | 6.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.
Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.
Altria Group (MO) trades at $71.68, up 3.31% with a bullish technical signal supported by moving averages. The stock shows strong profitability with 72.24% gross margins and 39% net income margin, though revenue has declined from $20.7B in 2022 to $20.1B in 2025. Recent earnings show mixed results with one beat and two misses in the last four quarters. The company maintains a substantial dividend yield with 60 consecutive increases, supported by $9.3B in operating cash flow.
MO presents a high-yield opportunity with analyst consensus favoring Buy ratings (61.5%), but faces significant risks including negative shareholder equity, declining margins, and regulatory pressures. The stock trades below the $69.71 consensus price target, suggesting limited upside potential. Investors must weigh the attractive 6.6% dividend yield against fundamental challenges in the core tobacco business and balance sheet concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
